[Therapeutic efficacy analysis of endoscopic combined with serological diagnosis strategy and endoscopic in G1 and G2 gastric neuroendocrine neoplasms].

W Y Li, Y Liu, Y M Zhang, L Z Dou, S He, Y Ke, X D Liu, Y M Liu, H R Wu, G Q Wang
{"title":"[Therapeutic efficacy analysis of endoscopic combined with serological diagnosis strategy and endoscopic in G1 and G2 gastric neuroendocrine neoplasms].","authors":"W Y Li, Y Liu, Y M Zhang, L Z Dou, S He, Y Ke, X D Liu, Y M Liu, H R Wu, G Q Wang","doi":"10.3760/cma.j.cn112152-20231219-00368","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> To investigate the endoscopic combined serological diagnosis strategy for G1 and G2 gastric neuroendocrine neoplasms (G-NENs), and to evaluate the safety, short-term, and long-term efficacy of two endoscopic treatment procedures: endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD). <b>Methods:</b> This study retrospectively analyzed the clinical data of 100 consecutive patients with G-NENs who were hospitalized at the Cancer Hospital of the Chinese Academy of Medical Sciences from January 2011 to October 2023. These patients underwent endoscopic treatment, and propensity score matching (PSM) was used to compare clinicopathological characteristics, as well as short-term and long-term efficacy of lesions in the EMR group and ESD group before and after treatment. <b>Results:</b> Among the 100 patients with G-NENs, the median age was 54 years old. Before surgery, 29 cases underwent endoscopic combined serological examination, and 24 of them (82.2%) had abnormally elevated plasma chromogranin A. The combined diagnostic strategy for autoimmune atrophic gastritis (AIG) achieved a diagnostic accuracy of 100%(22/22). A total of 235 G-NEN lesions were included, with 84 in the ESD group and 151 in the EMR group. The median size of the lesions in the ESD group (5.0 mm) was significantly larger than that in the EMR group (2.0 mm, <i>P</i><0.001). Additionally, the ESD group had significantly more lesions with pathological grade G2[23.8%(20/84) vs. 1.3%(2/151), <i>P</i><0.001], infiltration depth reaching the submucosal layer [78.6%(66/84) vs. 51.0%(77/151), <i>P</i><0.001], and more T2 stage compared to the EMR group[15.5%(13/84) vs. 0.7%(1/151), <i>P</i><0.001]. After PSM, 49 pairs of lesions were successfully matched between the two groups. Following PSM, there were no significant differences in the en bloc resection rate [100.0%(49/49) vs. 100.0%(49/49)], complete resection rate [93.9%(46/49) vs. 100.0%(49/49)], and complication rate [0(0/49) vs. 4.1%(2/49)] between the two groups. During the follow-up period, no recurrence or distant metastasis was observed in any of the lesions in both groups. <b>Conclusions:</b> The combination of endoscopy and serology diagnostic strategy has the potential to enhance the accuracy of diagnosing G1 and G2 stage G-NENs and their background mucosa. Endoscopic resection surgery (EMR, ESD) is a proven and safe treatment approach for G1 and G2 stage G-NENs.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华肿瘤杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112152-20231219-00368","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To investigate the endoscopic combined serological diagnosis strategy for G1 and G2 gastric neuroendocrine neoplasms (G-NENs), and to evaluate the safety, short-term, and long-term efficacy of two endoscopic treatment procedures: endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD). Methods: This study retrospectively analyzed the clinical data of 100 consecutive patients with G-NENs who were hospitalized at the Cancer Hospital of the Chinese Academy of Medical Sciences from January 2011 to October 2023. These patients underwent endoscopic treatment, and propensity score matching (PSM) was used to compare clinicopathological characteristics, as well as short-term and long-term efficacy of lesions in the EMR group and ESD group before and after treatment. Results: Among the 100 patients with G-NENs, the median age was 54 years old. Before surgery, 29 cases underwent endoscopic combined serological examination, and 24 of them (82.2%) had abnormally elevated plasma chromogranin A. The combined diagnostic strategy for autoimmune atrophic gastritis (AIG) achieved a diagnostic accuracy of 100%(22/22). A total of 235 G-NEN lesions were included, with 84 in the ESD group and 151 in the EMR group. The median size of the lesions in the ESD group (5.0 mm) was significantly larger than that in the EMR group (2.0 mm, P<0.001). Additionally, the ESD group had significantly more lesions with pathological grade G2[23.8%(20/84) vs. 1.3%(2/151), P<0.001], infiltration depth reaching the submucosal layer [78.6%(66/84) vs. 51.0%(77/151), P<0.001], and more T2 stage compared to the EMR group[15.5%(13/84) vs. 0.7%(1/151), P<0.001]. After PSM, 49 pairs of lesions were successfully matched between the two groups. Following PSM, there were no significant differences in the en bloc resection rate [100.0%(49/49) vs. 100.0%(49/49)], complete resection rate [93.9%(46/49) vs. 100.0%(49/49)], and complication rate [0(0/49) vs. 4.1%(2/49)] between the two groups. During the follow-up period, no recurrence or distant metastasis was observed in any of the lesions in both groups. Conclusions: The combination of endoscopy and serology diagnostic strategy has the potential to enhance the accuracy of diagnosing G1 and G2 stage G-NENs and their background mucosa. Endoscopic resection surgery (EMR, ESD) is a proven and safe treatment approach for G1 and G2 stage G-NENs.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[内镜联合血清学诊断策略与内镜对 G1 和 G2 胃神经内分泌肿瘤的疗效分析]。
目的研究 G1 和 G2 胃神经内分泌肿瘤(G-NENs)的内镜联合血清学诊断策略,并评估两种内镜治疗方法:内镜下粘膜切除术(EMR)和内镜下粘膜下剥离术(ESD)的安全性、短期和长期疗效。研究方法本研究回顾性分析了 2011 年 1 月至 2023 年 10 月期间在中国医学科学院肿瘤医院住院治疗的 100 例连续性 G-NENs 患者的临床数据。这些患者接受了内镜治疗,并采用倾向评分匹配法(PSM)比较了EMR组和ESD组患者治疗前后的临床病理特征以及病变的短期和长期疗效。结果100 名 G-NENs 患者的中位年龄为 54 岁。手术前,29 例患者接受了内镜联合血清学检查,其中 24 例(82.2%)血浆嗜铬粒蛋白 A 异常升高,自身免疫性萎缩性胃炎(AIG)联合诊断策略的诊断准确率达到 100%(22/22)。共纳入235例G-NEN病变,其中ESD组84例,EMR组151例。ESD组病变的中位尺寸(5.0毫米)明显大于EMR组(2.0毫米,P<0.001)。此外,ESD 组病理分级 G2[23.8%(20/84) vs. 1.3%(2/151),P<0.001]、浸润深度达到粘膜下层[78.6%(66/84)vs.51.0%(77/151),P<0.001],T2期较EMR组多[15.5%(13/84)vs.0.7%(1/151),P<0.001]。PSM 后,两组有 49 对病灶成功配对。PSM术后,两组的全切除率[100.0%(49/49) vs. 100.0%(49/49)]、完全切除率[93.9%(46/49) vs. 100.0%(49/49)]和并发症发生率[0(0/49) vs. 4.1%(2/49)]无明显差异。在随访期间,两组病灶均未发现复发或远处转移。结论是内镜检查和血清学诊断策略的结合有望提高诊断 G1 和 G2 期 G-NEN 及其背景粘膜的准确性。内镜下切除手术(EMR,ESD)是治疗G1和G2期G-NEN的一种行之有效且安全的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
中华肿瘤杂志
中华肿瘤杂志 Medicine-Medicine (all)
CiteScore
1.40
自引率
0.00%
发文量
10433
期刊介绍:
期刊最新文献
[International comparison and assessment of the quality of drug clinical trial implementation in China based on scientific regulatory system]. [A case of primary giant gastrointestinal stromal tumor of the liver]. [Chinese multidisciplinary expert consensus on the rational use of surufatinib in clinical practice(2024 edition)]. [Clinical predictive value of PD-1/PD-L1-induced electrocardiogram changes for cardiotoxicity]. [CT measurement of blood perfusion in hepatocellular carcinoma: from basic principle, measurement methods to clinical application].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1